Royalty Pharma plc Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Royalty Pharma plc (RPRX) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $6.33 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-15.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2022-02-15
- Royalty Pharma plc other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was $6.33M, a 89.55% decline from fiscal 2020.
- Royalty Pharma plc other comprehensive income (loss), before reclassifications, net of tax for fiscal 2020 was $60.62M, a 884.20% increase from fiscal 2019.
- Royalty Pharma plc other comprehensive income (loss), before reclassifications, net of tax for fiscal 2019 was $6.16M.
- Royalty Pharma plc other comprehensive income (loss), before reclassifications, net of tax for fiscal 2018 was -$402.50M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|
| 2021-12-31 | $6.33M 10-K · filed 2022-02-15 |
| 2020-12-31 | $60.62M 10-K · filed 2022-02-15 |
| 2019-12-31 | $6.16M 10-K · filed 2021-02-24 |
| 2018-12-31 | -$402.50M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |